Moreover, in in vitro and in NOD/SCID mouse models, lenalidomide blocked the adverse effects of both IL-6 and TGF-β1, adjuvating the anti-tumor effect of anti-GD2 immunotherapy [84]. This evidence concerns the gene TGFB1 and neoplasm.